0.38
+0.0049(+1.29%)
Currency In USD
| Previous Close | 0.38 |
| Open | 0.36 |
| Day High | 0.39 |
| Day Low | 0.36 |
| 52-Week High | 1.24 |
| 52-Week Low | 0.35 |
| Volume | 4.87M |
| Average Volume | 7.23M |
| Market Cap | 143.02M |
| PE | -0.86 |
| EPS | -0.45 |
| Moving Average 50 Days | 0.43 |
| Moving Average 200 Days | 0.52 |
| Change | 0 |
If you invested $1000 in Sangamo Therapeutics, Inc. (SGMO) 10 years ago, it would be worth $68.11 as of February 21, 2026 at a share price of $0.385. Whereas If you bought $1000 worth of Sangamo Therapeutics, Inc. (SGMO) shares 5 years ago, it would be worth $30.49 as of February 21, 2026 at a share price of $0.385.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
GlobeNewswire Inc.
Feb 03, 2026 9:05 PM GMT
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstr
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
GlobeNewswire Inc.
Feb 03, 2026 2:10 PM GMT
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded wa
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
GlobeNewswire Inc.
Dec 18, 2025 1:05 PM GMT
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support acce